How Does Influenza A (H1N1) Infection Proceed in Allogeneic Stem Cell Transplantation Recipients?

Influenza A (H1N1) İnfeksiyonu Allojeneik Nakil Hastalarında Nası Seyrediyor?

Sinem Civriz Bozdağ¹, Gülden Bozkurt², Pervin Topçuoğlu¹, Alpay Azap³, Muhit Özcan¹, Nahide Konuk¹, Önder Arslan¹

¹Ankara University, School of Medicine, Hematology Department, Ankara, Turkey
²Ankara University, School of Medicine, Infectious Diseases Department, Ankara, Turkey

Abstract

The clinical course of influenza A (H1N1) infection in allogeneic hematopoietic stem cell transplantation (AHSCT) recipients is not clearly known. We report 3 AHSCT recipients that were infected with influenza A (H1N1). Each of the patients had a different hematological disease and was at a different post-transplantation stages. All the patients were treated with oseltamivir, and zanamivir was switched to oseltamivir in 1 patient. All the patients survived without any complications. The course of swine flu can vary and progress with bacterial or other viral infections in immunosuppressed patients.

Key Words: H1N1, Allogeneic transplantation

Introduction

Viral infections cause morbidity and mortality in patients with hematological malignancies. The incidence and outcome of viral infections vary according to the intensity and duration of T-cell depletion. Allogeneic hematopoietic stem cell transplantation (AHSCT) recipients are highly susceptible to viral infections because of immunosuppression related to conditioning regimens, T-cell depletion, and graft versus host disease (GVHD) [1].

Influenza A (H1N1) in AHSCT recipients is associated with a wide range of symptoms. It can present with typical flu-like symptoms, such as fever, nausea, vomit-
ing, diarrhea, and headache, and sometimes with atypical symptoms. Patients with malignancies can have more serious manifestations, including respiratory failure [2]. Prolongation of viral shedding has been observed in immunosuppressed patients; therefore, treatment of infection can be a major problem [3]. Oseltamivir and zanamivir have been approved for the treatment of influenza [4]. Herein we present 3 AHSCT recipients with different hematologic malignancies that were diagnosed with influenza A (H1N1) infection during different post-transplant phases. Informed consent was obtained.

Case 1

A 23-year-old female acute myeloblastic leukemia (ALL) patient underwent AHSCT from an HLA fully matched cousin during her second complete remission in March 2009. She relapsed 7 months post transplantation and was admitted to the hospital with pancytopenia. A second transplantation from an alternative donor was scheduled and the patient subsequently underwent the 2nd allogeneic transplantation from another HLA fully matched cousin following the FLAMSA regimen in December 2009. Thoracic high-resolution computed tomography (HRCT) results one month before the second transplantation were normal. Paranasal tomography results were compatible with sinusitis and she was treated with levofloxacin. Three days before transplantation she had an attack of febrile neutropenia and cefaperazone-sulbactam and amikasin were initiated. Her blood culture was positive for E. coli ESBL and cefaperazone-sulbactam was replaced with imipenem. The patient had herpes labialis and valacyclovir was changed from a prophylactic dose to a treatment dose. Antifungal prophylaxis with fluconazole was replaced with posaconazole.

The patient was non-febrile for 9 d, and then developed fever and cough 6 d post transplantation. PCR test results for H1N1 were positive and oseltamivir 75 mg BID was given. Posteroanterior lung X Ray showed right perihilar and paracardiac consolidation. Thoracic HRCT was repeated and the findings were consistent with fungal infection. Posaconazole was stopped and liposomal amphotericin therapy was started. The patient’s fever was controlled for 6 d, but recurred the same day that neutrophil engraftment was performed As the patient’s cough persisted at the end of 5 days oseltamivir treatment, we decided to continue 5 more days. The patient’s attacks of fever were controlled and her cough was decreased by posttransplantation day 16.

Case 2

A 26-year-old male ALL patient underwent AHSCT from an unrelated donor during his second complete remission in July 2009. He did not have acute or chronic GVHD, but did have cytomegalovirus infection twice in 6 months, which was treated with ganciclovir. His immunosuppressive treatment was withdrawn 4 months post transplantation. As he had a history of disseminated fungal infection (Trichosporon) during chemotherapy, he continued to take voriconazole throughout the post-transplantation period. Antifungal therapy was stopped 2 months after the cessation of immunosuppressive therapy.

The patient had pancytopenia for 6 months and was admitted to the hospital in January 2010 with fever and cough. Piperacillin-tazobactam, oseltamivir, and voriconazole were started concomitantly. Posteroanterior lung X Ray showed reticulonodular infiltration in both lungs. PCR test results for H1N1 were positive. Oseltamivir 75mg BID was started with piperacillin-tazobactam and voriconazole. Thoracic HRCT showed ground glass density and a nodular appearance, which was considered indicative of viral and fungal pneumonia. Oseltamivir was withdrawn on d 6 of the treatment because of the patient’s fever persistence, and the development of anxiety, sinus tachycardia. Zanamivir was switched with oseltamivir for an additional 5 d, and then withdrawn. Sputum culture at the admission to the hospital, showed proliferation of Acinetobacter junii and the antibiotics were continued, according to the antibiogram. Piperacillin-tazobactam was replaced with imipenem and tigecycline. The patient’s fever persisted and antifungal therapy was continued. Sputum cultures during the antibiotic and antifungal therapies were found positive for enterococcus and Stenotrophomonas maltophilia. The day after the results of bronchoalveolar lavage (BAL) was performed and the same pathogens were noted in the BAL culture. The patient’s fever was controlled using ciprofloxacin. The patient’s cytomegalovirus titer increased after resolution of fever. Ganciclovir was prescribed for two weeks until the negativity of CMV titer was achieved.

Case 3

A 35-year-old male patient underwent AHSCT from an HLA fully matched sibling in November 2008, following autologous transplantation due to refractory Hodgkin’s disease. He had stable disease for 8 months after AHSCT. He was diagnosed as zona zoster at the end of 8 th month and treated with acyclovir treatment. PET/CT control at the ninth month was consistent with progressive disease,
Patients with hematological diseases and AHSCT recipients are highly susceptible to influenza A (H1N1). Several studies investigated the clinical spectrum of influenza A (H1N1) infection in AHSCT recipients [5,6]; fever and cough are the most common symptoms. All the presented patients had fever and cough at the time of presentation; case 2 had more severe respiratory symptoms than cases 1 and 3. Viruses such as influenza can cause symptoms following contact with an infected person, but none of the presented patients reported such contact.

The H1N1 virus most commonly affects individuals aged <25 years, such as the presented patients, but the H1N1-associated mortality is higher among those aged 25-49 years. All the presented patients survived H1N1 infection. The use of antiviral agents is not recommended for healthy individuals, unless symptoms persist >48 h. Nonetheless, treatment should be initiated in transplantation recipients regardless of the duration of symptoms. Early administration of oseltamivir improves outcome [4]. Oseltamivir was initiated with 48 h of fever in cases 2 and 3, and after the 2nd attack of fever and cough in case 1. Antibacterial treatment was administered to the 3 presented patients and altered according to culture results. Cases 1 and 2 had influenza A infection concomitant with fungal and bacterial infections. Cases 1 and 2 were treated for fungal and viral infection, respectively. Each of the presented patients was at a different post-transplantation phase.

The optimal dose of oseltamivir is a contentious issue that requires additional study. The presented patients were treated with oseltamivir 75 mg b.i.d., as they did not have gastrointestinal malabsorption due to chemotherapy or GVHD; however it is feasible to use higher doses in cases of high viral load and gastrointestinal absorption problems [4]. During the treatment of Case2 oseltamivir was switched to zanamivir due to the sinus tachycardia, anxiety side effects. There is no consensus concerning the optimal duration of oseltamivir treatment. As the symptoms in case 1 and 2 could not be controlled, treatment was administered for 10 d, but case 3 received oseltamivir for only 5 d.

The only way to prevent H1N1 infection is vaccination [7]. Post-transplantation immunosuppression remains a major problem for the immunogenicity of the H1N1 vaccine [8,9]. None of the presented patients had been vaccinated. The suspicion of our population about the effects and side effects of the vaccine was a problem to get over. In conclusion, based on our experience with the presented AHSCT patients with influenza A (H1N1) infection, we think that AHSCT patients may be highly susceptible to influenza, independent of the post-transplantation phase. All the presented patients received antiviral treatment and survived. The incidence and mortality has to be assessed in survey reports with large number of patients.

Conflicts of interest

The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

1. Whimbey E, Elting LS, Couch RB, et al: Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994; 13 (4): 437-440
2. Kharfan Dabaja MA, Velez A, Richards K, Greene J, Field T, Sandin R: Influenza A/pandemic 2009/H1N1in the setting of allogeneic hematopoietic stem cell transplantation: A potentially catastrophic problem in a vulnerable population. Int J Hematol 2010; 91 (1): 124-127
3. Weinstock DM, Gubareva LV, Zuccotti G: Prolonged shedding of multidrug resistant Influenza A virus in an immunocompromised patient. N Eng J Med 2003; 348: 867-868
4. Casper C, Englund J, Boeckh M: How I treat influenza in patients with hematologic malignancies. Blood 2010; 115 (7): 1331-1342
5. Hajjar LA, Mauad T, Galas FR, Kumar A, da Silva LF, Dohlhnikoff M, Trielli T, Almeida JP, Borsato MR, Abdalla E, Pierrot L, Filho RK, Auler JO Jr, Saldiva PH, Hoff PM: Severe novel Influenza A (H1N1) infection in cancer patients. Ann Oncol 2010; 21 (12): 2333-2341
6. Redelman-Sidi G, Sepkowitz KA, Huang CK, Park S, Stiles J, Eagan J, Perlin DS, Pamer EG, Kamboj M: 2009 H1N1 infection in cancer patients and hematopoietic stem cell transplant recipients. J Infect 2010; 60: 257-263
7. Avetisyan G, Aschan J, Hassan M, Ljungman P: Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 2008; 86 (2): 257-263

8. Engelhard D, Nagler A, Hardan I: Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell depleted and autologous BMT recipients. Bone Marrow Transplant 1993; 11: 1-5

9. Yalçın SS, Kondolot M, Albayrak N, Altaş AB, Karacan Y, Kuşkonmaz B, Aksu S, Cetin M, Goker H, Yurdakök K, Uçkan D: Serological response to influenza vaccine after hematopoetic stem cell transplantation. Ann Hematol 2010; 89 (9): 913-918

10. Ditschkowski M, Elmaagacli AH, Beelen DW: H1N1 in allogeneic stem cell recipients: Courses of infection and influence of vaccination on graft versus host disease. Ann Hematol 2011; 90 (1): 117-118